Familial aggregation and clinical prognosis of hepatitis B virus infection in Guangzhou,China

Ye JunZhao; Wu YanQin; Li Rui; Li ShaoFeng; Zhong BiHui

doi:10.3969/j.issn.1001-5256.2016.07.018

Issue 7

Jul. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(7): 1305-1309

PDF( 1534 KB)

Familial aggregation and clinical prognosis of hepatitis B virus infection in Guangzhou,China

DOI: 10.3969/j.issn.1001-5256.2016.07.018

Research funding:

Published Date: 2016-07-20

Abstract

Abstract

Objective To investigate the characteristics of familial aggregation and prognosis of chronic hepatitis B( CHB) in Guangzhou,China,where there is a high prevalence of hepatitis B virus( HBV) infection. Methods The CHB patients who were treated in Outpatient Department of Hepatitis in the First Affiliated Hospital of Sun Yat- sen University from January 2009 to April 2016 were enrolled. The basic demographic features,relatives' HBV markers,patients' HBV indices,liver biochemical parameters,and findings on liver color Doppler ultrasound,computed tomography( CT),and magnetic resonance imaging( MRI) were analyzed. Familial aggregation was defined as at least two relatives diagnosed with chronic HBV infection,and the clinical features were compared between the groups with and without familial aggregation. The t- test was used for comparison of normally distributed continuous data between groups,and the Wilcoxon rank sum test was used for non- normally distributed continuous data between groups. The chi- square test or Fisher' s exact test was used for comparison of categorical data between groups. The univariate logistic regression was used to analyze familial aggregation and the risk factors for HBV infection,liver cirrhosis,and liver cancer in offspring. Results A total of 1096 CHB patients with a clear family history were enrolled; among these patients,569 had a positive family history,resulting in a rate of familial aggregation of 51. 9%. According to their age,the patients were stratified into groups of 16- 30 years,31- 45 years,and > 46 years. The proportions of patients diagnosed with liver cirrhosis across the three age stratifications in the groups with and without familial aggregation were 2. 1% /11. 5% /35. 6% and 2. 7% /5. 7% /38. 5%,respectively. The group with familial aggregation had a significantly higher proportion of patients aged 31- 45 years who were diagnosed with liver cirrhosis than the group without familial aggregation( χ2= 5. 71,P = 0. 02). The familial aggregation pattern was dominated by infection between siblings( 30. 2%) and mother- children infection( 34. 4%). Maternal and paternal infection( OR = 8. 18,95% CI: 5. 24-12. 75),maternal infection alone( OR = 4. 60,95% CI: 3. 69- 5. 74),and paternal infection alone( OR = 2. 77,95% CI: 2. 11- 3. 63)were associated with HBV infection in offspring. Familial aggregation pattern was not the risk factor for the development of liver cirrhosis in patients( P > 0. 05),while maternal and paternal infection( OR = 8. 5,P < 0. 01) was the risk factor for the development of liver cancer.Conclusion CHB infection shows high familial aggregation in Guangzhou,and the patients with a positive family history of CHB may progress to liver cirrhosis early.
- hepatitis B,
- chronic,
- familial aggregation

FullText(HTML)

References(13)

References

[1]SARIN SK,KUMAR M,LAU GK,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int,2016,10(1):1-98.

[2]YANG Y,JIN L,HE YL,et al.Hepatitis B virus infection in clustering of infection in families with unfavorable prognoses in northwest China[J].J Med Virol,2013,85(11):1893-1899.

[3]ZHU B,RONG YH,LIU HL,et al.Clinical characteristics of hepatitis B virus-related acute-on-chronic liver failure patients with familial aggregation[J].Chin J Exp Clin Virol,2011,25(6):460-462.(in Chinese)朱冰,荣义辉,刘鸿凌,等.家族聚集性HBV相关慢加急性肝衰竭患者临床特点分析[J].中华实验和临床病毒学杂志,2011,25(6):460-462.

[4]YU MW,CHANG HC,CHEN PJ,et al.Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan[J].Int J Epidemiol,2002,31(5):1008-1015.

[5]GAO Y,JIANG Q,ZHOU X,et al.HBV infection and familial aggregation of liver cancer:an analysis of case-control family study[J].Cancer Causes Control,2004,15(8):845-850.

[6]SHAO FZ,SHI BA,LIU WQ,et al.The relationships among HBVgenotypes,HBV DNA levels and histopathological features in the livers of familial grouped hepatitis B patients in the Tianjin area[J].Chin J Hepatol,2007,15(1):16-18.(in Chinese)邵凤珍,施伯安,刘文全,等.天津地区家族聚集性慢性乙型肝炎病毒感染者病毒载量及组织病变与基因型的关系[J].中华肝脏病杂志,2007,15(1):16-18.

[7]PANG XH,WANG H,MA JX,et al.Study on family aggregation and risk factors of hepatitis B virus transmission in Chaoyang district,Beijing[J].Chin J Epidemibol,2012,46(9):818-821.(in Chinese)庞星火,王怀,马建新,等.北京市朝阳区乙型肝炎病毒感染家庭聚集性及传播危险因素研究[J].中华预防医学杂志,2012,46(9):818-821.

[8]GUPTA S,GUPTA R,JOSHI YK,et al.Role of horizontal transmission in hepatitis B virus spread among household contacts in north India[J].Intervirology,2008,51(1):7-13.

[9]ZENG XX,ZENG ZC,SUN LY,et al.Sero-epidemiological survey of hepatitis B virus infection in different populations in Hainan province[J].China Trop Med,2008,8(11):1894-1897,1905.(in Chinese)曾雪霞,曾昭长,孙莲英,等.海南省全国人群病毒性乙型肝炎血清流行病学调查[J].中国热带医学,2008,8(11):1894-1897,1905.

[10]LU W,ZHOU Y,XIE JX,et al.Epidemic survey of familial clustering risk factors for hepatitis B in Shanghai area[J].Acad J Second Military Med Univ,2009,30(10):1162-1165.(in Chinese)陆伟,周赟,谢佳新,等.上海地区乙型肝炎家庭聚集性危险因素的流行病学调查[J].第二军医大学学报,2009,30(10):1162-1165.

[11]LI J,LIU JY,HU JY,et al.Study on the status of HBV infection and its determinants among family members with HBV infected persons in Shanghai[J].Chin J Epidemiol,2013,34(3):205-209.(in Chinese)黎健,刘景壹,胡家瑜,等.上海市乙型肝炎感染者家庭成员感染状况及影响因素分析[J].中华流行病学杂志,2013,34(3):205-209.

[12]ZHU JY,YAN YM,MA DR.Analysis infection module in families by carrying HBV[J].Prev Med Trib,2006,12(2):148-150.(in Chinese)朱建勇,严玉明,马道瑞.卫辉市部分乙肝感染者家庭的感染模式分析[J].预防医学论坛,2006,12(2):148-150.

[13]POURNIK O,ALAVIAN SM,GHALICHI L,et al.Lower intrafamilial transmission rate of hepatitis B in patients with hepatitis Dcoinfection:a data-mining approach[J].Hepat Mon,2013,13(5):e7652.

Relative Articles

[1]	Xiaoxuan XIE, Lina DU, Ziyun GUO, Yan YANG. Role of apical sodium-dependent bile acid transporter in hepatobiliary diseases[J]. Journal of Clinical Hepatology, 2024, 40(1): 199-203. doi: 10.12449/JCH240133
[2]	Long HUANG, Yu CHEN, Qiao WU, Zhongping DUAN. Effect of Shuganning injection on the model of cholestasis - type chlorpromazine - induced liver injury constructed by a new tissue - engineered liver[J]. Journal of Clinical Hepatology, 2022, 38(3): 587-593. doi: 10.3969/j.issn.1001-5256.2022.03.018
[3]	Huaqian XU, Meng WEI, Xue ZHANG, Hai YI, Fangyi FAN, Aiping HUANG, Shanhong TANG. Diffuse large B-cell lymphoma with severe cholestasis as the main manifestation: A case report[J]. Journal of Clinical Hepatology, 2022, 38(12): 2821-2823. doi: 10.3969/j.issn.1001-5256.2022.12.025
[4]	Bo YI, Xue LI, Shanhong TANG. Research advances in the mechanism of abnormal bile acid metabolism caused by gene mutation[J]. Journal of Clinical Hepatology, 2022, 38(9): 2136-2140. doi: 10.3969/j.issn.1001-5256.2022.09.036
[5]	Xiaoqiang GAO, Shi ZUO, Xiaodong JIA, Yinying LU. Research advances in sodium taurocholate cotransporting polypeptide in hepatobiliary diseases[J]. Journal of Clinical Hepatology, 2022, 38(5): 1179-1182. doi: 10.3969/j.issn.1001-5256.2022.05.043
[6]	Jing LI, Kuiyang ZHENG, Beibei ZHANG. Mechanism of action of bile acid metabolism in regulating cholestatic liver disease and the research and development of drugs[J]. Journal of Clinical Hepatology, 2021, 37(10): 2482-2487. doi: 10.3969/j.issn.1001-5256.2021.10.048
[7]	WU Rong, LING AiMin. Primary biliary cirrhosis with autoimmune hemolytic anemia: A case report[J]. Journal of Clinical Hepatology, 2020, 36(12): 2795-2797. doi: 10.3969/j.issn.1001-5256.2020.12.030
[8]	Hua HaiYang, Li JianHui, Su Bin, Xuan XiaoYu. Liver subcapsular biliary cyst successfully treated by endoscopic retrograde cholangiopancreatography: A case report[J]. Journal of Clinical Hepatology, 2020, 36(6): 1354-1355. doi: 10.3969/j.issn.1001-5256.2020.06.034
[9]	Shen Hong, Hu Meng, Wei ZeHui, Zhang Dong, Zhang JunChang, Tian GuangJun. Bile formation, secretion, and excretion and the pathogenesis of cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(2): 431-437. doi: 10.3969/j.issn.1001-5256.2019.02.043
[10]	Zhou Fang, Li XiaoQin, Wang RuiFeng, Sun Bo. X-linked lymphoproliferative disease type 2 with cholestatic liver disease as initial manifestation: A case report[J]. Journal of Clinical Hepatology, 2019, 35(8): 1811-1814. doi: 10.3969/j.issn.1001-5256.2019.08.034
[11]	Kan YanTing, Yang YongFeng. Role of cholestatic liver disease-related genes in intrahepatic cholestasis of pregnancy[J]. Journal of Clinical Hepatology, 2019, 35(7): 1439-1443. doi: 10.3969/j.issn.1001-5256.2019.07.006
[12]	Song YuanZong. Research advances in the pathogenesis, clinical manifestations, and diagnosis/treatment of sodium-taurocholate cotransporting polypeptide deficiency[J]. Journal of Clinical Hepatology, 2019, 35(8): 1690-1692. doi: 10.3969/j.issn.1001-5256.2019.08.007
[13]	Xu Feng, Liu XiaoLin, Wang Chao, Dai ChaoLiu. Protective effect of prostaglandin E1 pretreatment against liver ischemia-reperfusion injury in rats with cholestasis[J]. Journal of Clinical Hepatology, 2017, 33(5): 899-904. doi: 10.3969/j.issn.1001-5256.2017.05.022
[14]	Zhang XuQian, Zhao ChunShan, Liu WenTian, Wang BangMao, Zhou Lu. Elevated serum GGT level in recovery phase of cholestatic liver disease reveals good prognosis: a case report [J]. Journal of Clinical Hepatology, 2016, 32(4): 774-775. doi: 10.3969/j.issn.1001-5256.2016.04.037
[15]	Shen FeiFei, Lu LunGen. Liver alkaline phosphatase: a marker of cholestasis and bile duct injury[J]. Journal of Clinical Hepatology, 2016, 32(5): 1026-1030. doi: 10.3969/j.issn.1001-5256.2016.05.052
[16]	Li Hua, Li YiMing, Lu Le. Mechanism of α-naphthyl isothiocyanate inducing cholestatic hepatitis: a preliminary study[J]. Journal of Clinical Hepatology, 2016, 32(5): 933-937. doi: 10.3969/j.issn.1001-5256.2016.05.026
[17]	Li Lei, Li Bing, Ding HuiGuo. Effect of ursodeoxycholic acid on bile secretion after endoscopic nasobiliary drainage in patients with cholestatic liver disease of various causes[J]. Journal of Clinical Hepatology, 2016, 32(3): 522-525. doi: 10.3969/j.issn.1001-5256.2016.03.026
[18]	Guo HongMei, Zheng BiXia, Li Mei. Neonatal intrahepatic cholestasis caused by citrin deficiency due to SLC25A13 gene mutations: a clinical analysis of 21cases in Nanjing, China[J]. Journal of Clinical Hepatology, 2014, 30(11): 1127-1131. doi: 10.3969/j.issn.1001-5256.2014.11.008
[19]	Lu LunGen. Mechanism of bile secretion, excretion, regulation and cholestasis[J]. Journal of Clinical Hepatology, 2011, 27(6): 570-571+580.
[20]	Qu Ying, Xu MingYi, Lu LunGen. Current progress in understanding of cholestasis and autoimmune liver diseases——Meeting review about 1st symposium on cholestasis and autoimmune liver disease[J]. Journal of Clinical Hepatology, 2011, 27(2): 222-225.

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	张连峰，杨丽敏. 胸腺肽肠溶片联合聚乙二醇干扰素对慢性肝炎患者的治疗效果及其相关指标的影响. 中国当代医药. 2020(04): 50-52 .
2.	王雪云，孙敏，赵巧云，李红军，王先芝，郑玉山，边城. 聚乙二醇干扰素联合富马酸替诺福韦治疗慢性乙型肝炎的疗效观察. 医学信息. 2020(04): 144-146 .
3.	刘征. 恩替卡韦联合α-干扰素对慢性乙型肝炎患者血清ALT复常率的影响. 淮海医药. 2020(02): 181-183 .
4.	李淑，彭雁忠，胡国信，齐明华，武敬. 聚乙二醇干扰素治疗低水平HBsAg慢性乙肝患者疗效. 中国热带医学. 2020(07): 676-681 .
5.	嵇玮嘉，颜学兵. 聚乙二醇干扰素α-2a与聚乙二醇干扰素α-2b治疗慢性乙型肝炎的效果及安全性比较. 临床肝胆病杂志. 2019(02): 309-314 . 本站查看
6.	吴明杰. 聚乙二醇干扰素α-2b对慢性乙型肝炎的作用分析. 中国继续医学教育. 2019(12): 142-144 .
7.	张珊，王艺璇，孙静，朱琳，王凤水，邢卉春. 干扰素联合抗病毒治疗对提高核苷（酸）类药物经治慢性乙型肝炎患者表面抗原阴转率的影响. 中华实验和临床感染病杂志(电子版). 2019(04): 273-280 .
8.	郭志勇，贺文娟，裴军芳. 聚乙二醇干扰素α-2a注射液联合替诺福韦酯治疗e抗原阳性慢性乙型肝炎疗效分析. 中国药物与临床. 2019(22): 3944-3946 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2040) PDF downloads(422)

Familial aggregation and clinical prognosis of hepatitis B virus infection in Guangzhou,China

DOI: 10.3969/j.issn.1001-5256.2016.07.018